文章摘要
丁婷婷,陈 军,李仙龙,孙 沫,王永贵,庚俐莉.盐酸氨溴索辅助治疗对慢性阻塞性肺病患者血清BNP, TNF-α及脂联素水平的影响[J].,2017,17(5):901-904
盐酸氨溴索辅助治疗对慢性阻塞性肺病患者血清BNP, TNF-α及脂联素水平的影响
Effects of Ambroxol Hydrochloride Adjuvant Therapy on the Levels of Serum BNP, TNF-α and Adiponectin in Patients with Chronic Obstructive Pulmonary Disease
投稿时间:2016-08-10  修订日期:2016-08-29
DOI:10.13241/j.cnki.pmb.2017.05.026
中文关键词: 盐酸氨溴索  辅助治疗  慢性阻塞性肺病  脂联素
英文关键词: Ambroxol hydrochloride  Adjuvant therapy  Chronic obstructive pulmonary disease  Adiponectin
基金项目:安徽省自然科学基金项目(07041306)
作者单位
丁婷婷 滁州市第一人民医院 呼吸内科 安徽 滁州 239000 
陈 军 滁州市第一人民医院 呼吸内科 安徽 滁州 239000 
李仙龙 滁州市第一人民医院 呼吸内科 安徽 滁州 239000 
孙 沫 滁州市第一人民医院 呼吸内科 安徽 滁州 239000 
王永贵 滁州市第一人民医院 呼吸内科 安徽 滁州 239000 
庚俐莉 大连医科大学附属大连市中心医院 呼吸科 辽宁 大连 116033 
摘要点击次数: 238
全文下载次数: 107
中文摘要:
      摘要 目的:探究盐酸氨溴索辅助治疗对慢性阻塞性肺病患者血清脑钠肽BNP,肿瘤坏死因子(TNF-α)及脂联素(APN)水平影响。方法:收集我院收治的慢性阻塞性肺病患者患者70例,根据随机对照表分为对照组和试验组,其中试验组35例,对照组35例,对照组给予茶碱缓释片治疗,试验组在对照组的基础上予以盐酸氨溴索注射液治疗。观察并对比两组患者的临床疗效、肺功能、血清BNP、TNF-α、APN水平及不良反应发生情况。结果:治疗后与对照组相比,试验组临床总有效率较高(P<0.05)。治疗后两组FEV1、FEV1/FVC以及FEV1占预计值升高(P<0.05),与对照组相比,治疗组FEV1、FEV1/FVC以及FEV1占预计值较高(P<0.05)。治疗后两组血清BNP、TNF-α以及APN水平下降(P<0.05),与对照组相比,治疗组血清BNP、TNF-α以及APN水平较低(P<0.05)。两组不良反应发生情况相比,差异无统计学意义(P>0.05)。结论:盐酸氨溴索辅助治疗慢性阻塞性肺病患者临床疗效显著,可下调BNP、TNF-α以及脂联素水平。
英文摘要:
      ABSTRACT Objective: To investigate the effects of ambroxol hydrochloride adjuvant therapy on the levels of serum brain natriuretic peptide (BNP), tumor necrosis factor-α (TNF-α) and adiponectin (APN) in patients with chronic obstructive pulmonary disease. Methods: 70 patients with chronic obstructive pulmonary disease who were treated in our hospital were selected and randomly divided into experi- ment group and control group, with 35 cases in each group. The patients in two groups were given anti-infection, oxygen inhalation, ex- pectorant, spasmolysis and defervesce conventional treatment, and the patients in the control group were treated with theophylline sus- tained-release tablets, and the patients in the experiment group were treated on the base of the control group with ambroxol hydrochlo- ride injection. The clinical efficacy, pulmonary function, serum BNP, TNF-α and APN levels and adverse reactions were compared and analyzed in the two groups after treatment. Results: Compared with the control group, the clinical total effective rate of the experiment group was higher after treatment (P<0.05). Compared with before treatment, the FEV1, FEV1 / FVC and FEV1 in the two groups in- creased after treatment (P<0.05); Compared with the control group, the FEV1, FEV1 / FVC and FEV1 in the experiment group were higher (P<0.05). Compared with before treatment, the serum levels of BNP, TNF-α and APN in the two groups decreased after treatment (P<0.05); Compared with the control group, the serum levels of BNP, TNF-α and APN in the experiment group were lower (P<0.05). There was no statistically significant difference of the incidence of adverse reactions between two groups (P>0.05). Conclusion: Am- broxol hydrochloride adjuvant therapy patients has remarkable clinical efficacy in treatment of chronic obstructive pulmonary disease, which may be related to the reduction of the serum levels of BNP and TNF-α and APN.
查看全文   查看/发表评论  下载PDF阅读器
关闭